Relation between gut microbiome and inflammatory interleukins in psoriasis patients compared to healthy controls: an observational study L. Schneller-Pavelescu; C. Mora-Martínez; MJ. Sánchez-Pujol; Y. Sanz; E. Caparrós-Cayuela; R. Francés-Guarinos; JM. Ramos-Rincón; I. Belinchón-Romero;

Tildrakizumab 200 mg. Is double dosing really a window of opportunity? Carlos Llamas-Segura; Marta Cebolla-Verdugo; Ricardo Ruiz-Villaverde;

Mortality outcomes in patients with plaque psoriasis and hidradenitis suppurativa: the role of biologic therapy R. Rivera-Díaz; B. Joven; A. Gotor-Rivera; J. Hernández;